.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,438,203

« Back to Dashboard

Details for Patent: 7,438,203

Title:Dermal penetration enhancers and drug delivery systems involving same
Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.
Inventor(s): Reed; Barry Lenard (Strathmore, AU), Morgan; Timothy Matthias (Carlton North, AU), Finnin; Barrie Charles (Glen Iris, AU)
Assignee: Acrux DDS Pty Ltd (Victoria, AU)
Filing Date:Jan 20, 2004
Application Number:10/759,303
Claims:1. An apparatus for appying a metered dose of a non-occlusive percutaneous or non-occlusive transdermal drug delivery system comprising a physiologically active agent or prodrug thereof to a dermal surface of an animal, comprising: (A) a container, (B) a metered dose applicator selected from the group consisting of a metered dose aerosol, a stored energy metered dose pump, and a manual metered dose pump, wherein said container contains (C) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises: (1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof; and (2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface and (ii) is of low toxicity to and is tolerated by the dermal surface of the animal, and wherein, after application of the system to an area of the dermal surface, the area becomes touch-dry within three minutes of application, and wherein the physiologically active agent is a hormone for contraception or hormone replacement therapy.

2. An apparatus for applying a metered dose of a non-occlusive percutaneous or non-occlusive transdermal drug delivery system comprising a physiologically active agent or prodrug thereof to a dermal surface of an animal, comprising: (A) a container, (B) a metered dose applicator selected from the group consisting of a metered dose aerosol, a stored energy metered dose pump, and a manual metered dose pump, wherein said container contains (C) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises: (1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof and (2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface and (ii) is of low toxicity to and is tolerated by the dermal surface of the animal, and wherein, after application of the system to an area of the dermal surface, the area becomes touch-dry within three minutes of application, and wherein the physiologically active agent comprises a progestogen other than progesterone.

3. An apparatus for applying a metered dose of a non-occlusive percutaneous or non-occlusive transdermal drug delivery system comprising a physiologically active agent or prodrug thereof to a dermal surface of an animal, comprising: (A) a container, (B) a metered dose applicator selected from the group consisting of a metered dose aerosol, a stored energy metered dose pump, and a manual metered dose pump, wherein said container contains (C) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises: (1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof; and (2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface and (ii) is of low toxicity to and is tolerated by the dermal surface of the animal, and wherein, after application of the system to an area of the dermal surface, the area becomes touch-dry within three minutes of application, and wherein the physiologically active agent comprises an oestrogen and a progestogen other than progesterone.

4. An apparatus for applying a metered dose of a non-occlusive percutaneous or non-occlusive transdermal drug delivery system comprising a physiologically active agent or prodrug thereof to a dermal surface of an animal, comprising: (A) a container, (B) a metered dose applicator selected from the group consisting of a metered dose aerosol, a stored energy metered dose pump, and a manual metered dose pump, wherein said container contains (C) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises: (1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof; and (2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface and (ii) is of low toxicity to and is tolerated by the dermal surface of the animal, and wherein, after application of the system to an area of the dermal surface, the area becomes touch-dry within three minutes of application, and wherein the active agent comprises at least one active agent selected from the group consisting of oestradiol, oestriol, oestrone, ethinyloestradiol, mestranol, stilboestrol, dienoestrol, epioestriol, estropipate, zeranol, progesterone, allyloestrenol, dydrogesterone, lynoestrenol, norgestrel, norethyndrel, norethisterone, norethisterone acetate, gestodene, levenorgestrel, medroxyprogesterone and megestrol.

5. An apparatus for applying a metered dose of a non-occlusive percutaneous or non-occlusive transdermal drug delivery system comprising a physiologically active agent or prodrug thereof to a dermal surface of an animal, comprising: (A) a container, (B) a metered dose applicator selected from a metered dose aerosol, a stored energy metered dose pump and a manual metered dose pump, wherein said container contains (C) a non-occlusive percutaneous or non-occlusive transdermal drug delivery system that comprises: (1) a therapeutically effective amount of at least one physiologically active agent or prodrug thereof and at least one dermal penetration enhancer, which is present in an amount of from 10 to 10,000 wt % based on the weight of the active agent or prodrug thereof; and (2) at least one volatile liquid present in an amount to act as a vehicle for the active agent and penetration enhancer, wherein the physiologically active agent comprises an oestrogen, and wherein the dermal penetration enhancer (i) is adapted to transport the physiologically active agent across a dermal surface of an animal, when the volatile liquid evaporates, to form a reservoir or depot of a mixture comprising the penetration enhancer and the physiologically active agent within said surface and (ii) is of low toxicity to and is tolerated by the dermal surface of the animal, and wherein, after application of a metered dose of the system to an area of the dermal surface, the area becomes touch-dry within three minutes of application.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc